

Amniotics granted U.S. patent for its oncology program AMNI-NK003

Amniotics (publ) (Nasdaq Stockholm: AMNI) today announced that the US Patent and Trademark Office (USPTO) has approved a patent application that supports the company's anti-cancer platform AMNI-NK003. This newly allowed U.S. patent, with application no.16 /343617, "Methods and compositions for generating hematopoietic cells" is the first patent for Amniotics to be granted within this field.

Amniotics co-founder Niels Bjarne Woods and colleagues at Lund University have described this novel mechanism that can be used to enhance blood development in vitro to specific blood lineages and thereby increase the production and purity of desired cell types. AMNI-NK003 aims to produce cells with strong antitumor activity, so called Natural Killer (NK) cells. NK cell therapies have been shown in several clinical studies to be effective against both hematological and solid tumors.

"This US patent makes it possible for us to accelerate our anti-cancer platform to generate truly off-the-shelf NK cell therapies to fight cancer. We see great potential in the field, which is the reason why AMNI-NK003 is now a part of our prioritized product portfolio. This milestone has been reached through a team effort, and I want to take the opportunity to thank our co-founder Niels Bjarne Woods, our corporate patent advisor Dominic Davies and our US IP partner Knobbe Martens", says Marcus Larsson, CEO at Amniotics.

About AMNI-NK003

Amniotics anti-cancer program AMNI-NK003 is focusing on generating off-the-shelf Natural Killer (NK) cells from induced pluripotent stem cells (iPS) targeting hematological and solid cancers. NK cell therapy is a new therapeutic approach that uses immune cells to attack tumors. The difficulty to manufacture large quantities of NK cells has hampered the progress. AMNI-NK003 is designed to produce NK cells with high anti-tumor efficacy more efficiently. The program is in pre-clinical phase and next steps include process development under GMP.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

or
Johnny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 735 0668 56
Email: jh@amniotics.com

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

Attachments

Amniotics granted U.S. patent for its oncology program AMNI-NK003